-
Something wrong with this record ?
Acid-responsive HPMA copolymer-bradykinin conjugate enhances tumor-targeted delivery of nanomedicine
E. Appiah, H. Nakamura, R. Pola, E. Grossmanová, O. Lidický, A. Kuniyasu, T. Etrych, M. Haratake
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Bradykinin therapeutic use MeSH
- Doxorubicin therapeutic use MeSH
- Methacrylates MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Neoplasms * drug therapy MeSH
- Nanomedicine MeSH
- Drug Carriers therapeutic use MeSH
- Polymers therapeutic use MeSH
- Antineoplastic Agents * therapeutic use MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Obstructed blood flow and erratic blood supply in the tumor region attenuate the distribution and accumulation of nanomedicines in the tumor. Therefore, improvement of these conditions is crucial for efficient drug delivery. In this study, we designed and synthesized a novel N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer conjugate of BK, which possessed adequate systemic stability and tumor-selective action required to improve the accumulation of nanomedicines in the tumor. Levulinoyl-BK (Lev-BK) was conjugated to an HPMA-based polymer via an acid-cleavable hydrazone bond (P-BK). An acid-responsive release of Lev-BK from P-BK was observed, and P-BK alone after intradermal application showed below 10% of the BK activity, thus proving a reduction in the vascular permeability activity of BK when attached to the polymer carrier. P-BK pre-treatment improved blood flow in the tumor tissue by 1.4-1.7-fold, which was maintained for more than 4 h. In addition, P-BK pre-treatment increased the tumor accumulation of pegylated liposomal doxorubicin (PLD) by approximately 3-fold. Furthermore, P-BK pre-treatment led to superior antitumor activity of PLD and significantly improved the survival of tumor-bearing mice. The release of BK from P-BK in the acidic milieu of the tumor was a prerequisite for P-BK to exert its effect, as the vascular permeability enhancing activity of P-BK was negligible. Collectively, P-BK pre-treatment improved intratumoral blood flow and augmented tumor accumulation of nanomedicine, thereby resulting in a significant suppression of tumor growth. Therefore, these findings demonstrate that P-BK is a potential concomitant drug for improving the tumor delivery of nanomedicines.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003745
- 003
- CZ-PrNML
- 005
- 20220127145919.0
- 007
- ta
- 008
- 220113s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jconrel.2021.08.009 $2 doi
- 035 __
- $a (PubMed)34375687
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Appiah, Enoch $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan
- 245 10
- $a Acid-responsive HPMA copolymer-bradykinin conjugate enhances tumor-targeted delivery of nanomedicine / $c E. Appiah, H. Nakamura, R. Pola, E. Grossmanová, O. Lidický, A. Kuniyasu, T. Etrych, M. Haratake
- 520 9_
- $a Obstructed blood flow and erratic blood supply in the tumor region attenuate the distribution and accumulation of nanomedicines in the tumor. Therefore, improvement of these conditions is crucial for efficient drug delivery. In this study, we designed and synthesized a novel N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer conjugate of BK, which possessed adequate systemic stability and tumor-selective action required to improve the accumulation of nanomedicines in the tumor. Levulinoyl-BK (Lev-BK) was conjugated to an HPMA-based polymer via an acid-cleavable hydrazone bond (P-BK). An acid-responsive release of Lev-BK from P-BK was observed, and P-BK alone after intradermal application showed below 10% of the BK activity, thus proving a reduction in the vascular permeability activity of BK when attached to the polymer carrier. P-BK pre-treatment improved blood flow in the tumor tissue by 1.4-1.7-fold, which was maintained for more than 4 h. In addition, P-BK pre-treatment increased the tumor accumulation of pegylated liposomal doxorubicin (PLD) by approximately 3-fold. Furthermore, P-BK pre-treatment led to superior antitumor activity of PLD and significantly improved the survival of tumor-bearing mice. The release of BK from P-BK in the acidic milieu of the tumor was a prerequisite for P-BK to exert its effect, as the vascular permeability enhancing activity of P-BK was negligible. Collectively, P-BK pre-treatment improved intratumoral blood flow and augmented tumor accumulation of nanomedicine, thereby resulting in a significant suppression of tumor growth. Therefore, these findings demonstrate that P-BK is a potential concomitant drug for improving the tumor delivery of nanomedicines.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a bradykinin $x terapeutické užití $7 D001920
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a doxorubicin $x terapeutické užití $7 D004317
- 650 _2
- $a nosiče léků $x terapeutické užití $7 D004337
- 650 _2
- $a methakryláty $7 D008689
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a nanomedicína $7 D050997
- 650 12
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a polymery $x terapeutické užití $7 D011108
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Nakamura, Hideaki $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan. Electronic address: nhideaki@ph.sojo-u.ac.jp
- 700 1_
- $a Pola, Robert $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic
- 700 1_
- $a Grossmanová, Eliška $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic
- 700 1_
- $a Lidický, Ondřej $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic
- 700 1_
- $a Kuniyasu, Akihiko $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan
- 700 1_
- $a Etrych, Tomáš $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic. Electronic address: etrych@imc.cas.cz
- 700 1_
- $a Haratake, Mamoru $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan
- 773 0_
- $w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 337, č. - (2021), s. 546-556
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34375687 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145915 $b ABA008
- 999 __
- $a ok $b bmc $g 1751255 $s 1154894
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 337 $c - $d 546-556 $e 20210808 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
- LZP __
- $a Pubmed-20220113